New strategy aims to shield transplant patients from dangerous virus rebound
NCT ID NCT06407232
Summary
This study is testing if a drug called letermovir can prevent a common and serious virus (CMV) from coming back in kidney or kidney/pancreas transplant patients who have just been treated for an infection. About 90 adult patients at UW Health who are at high risk for CMV will take letermovir daily for about 6 months. The goal is to see if this approach is better and safer than the current standard treatment by reducing side effects and helping the body's own immune system fight the virus.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.